- Home
- RYN vs ACLX Comparison
RYN vs ACLX Comparison
Compare RYN & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- ACLX
- Stock Information
- Founded
- RYN 1926
- ACLX 2015
- Country
- RYN United States
- ACLX United States
- Employees
- RYN N/A
- ACLX N/A
- Industry
- RYN Real Estate Investment Trusts
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- ACLX Health Care
- Exchange
- RYN Nasdaq
- ACLX Nasdaq
- Market Cap
- RYN 3.5B
- ACLX 3.5B
- IPO Year
- RYN N/A
- ACLX 2022
- Fundamental
- Price
- RYN $23.10
- ACLX $67.16
- Analyst Decision
- RYN Hold
- ACLX Strong Buy
- Analyst Count
- RYN 4
- ACLX 14
- Target Price
- RYN $27.75
- ACLX $111.42
- AVG Volume (30 Days)
- RYN 1.1M
- ACLX 567.9K
- Earning Date
- RYN 08-06-2025
- ACLX 08-07-2025
- Dividend Yield
- RYN 12.51%
- ACLX N/A
- EPS Growth
- RYN 108.38
- ACLX N/A
- EPS
- RYN 2.33
- ACLX N/A
- Revenue
- RYN $1,233,027,000.00
- ACLX $76,809,000.00
- Revenue This Year
- RYN N/A
- ACLX N/A
- Revenue Next Year
- RYN $3.99
- ACLX $112.68
- P/E Ratio
- RYN $9.78
- ACLX N/A
- Revenue Growth
- RYN 17.89
- ACLX N/A
- 52 Week Low
- RYN $21.84
- ACLX $47.86
- 52 Week High
- RYN $32.88
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- RYN 49.81
- ACLX 59.84
- Support Level
- RYN $21.84
- ACLX $63.13
- Resistance Level
- RYN $23.30
- ACLX $67.83
- Average True Range (ATR)
- RYN 0.51
- ACLX 2.52
- MACD
- RYN 0.06
- ACLX 0.14
- Stochastic Oscillator
- RYN 62.69
- ACLX 90.30
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.